<DOC>
	<DOCNO>NCT02333474</DOCNO>
	<brief_summary>The purpose study evaluate safeness effectiveness mix vaccine ( MV ) . Enrolled patient receive standard treatment accord National Comprehensive Cancer Network ( NCCN ) guide line without combine MV injection . The efficacy side effect compare two group .</brief_summary>
	<brief_title>Safety Efficacy Mix Vaccine Lung Carcinoma Patient</brief_title>
	<detailed_description>In study , evaluation general physical status , eligible patient enrol randomly assign two arm 1:1 ratio . In control arm patient receive standard therapy accord National Comprehensive Cancer Network ( NCCN ) guide line ( control group ) experimental arm , patient receive simultaneous standard therapy injection mix vaccine ( MV ) . MV inject weekly till disease progression . Blood sample obtain baseline every week MV injection assessment clinical hematology , biochemistry measurement immunology index ( include immunoglobin , interleukin interferon ) . Patients evaluate toxicity throughout study . Side effect , progression free survival , immunology index general status record .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Patients diagnose lung carcinoma base histology 2 . Evaluable lesion image study 3 . Without known immunodeficiency 4 . Age &gt; 18 &lt; 80 year ago 1 . Patients unable unwilling sign inform consent 2 . Any autoimmune disorder , currently treat prednisone immune suppressive medication 3 . Positive HIV and/or RPR ( rapid plasma reagin ) 4 . Female patient pregnant breast feed 5 . Patients , base opinion pf investigator , enrol study 6 . Prior anticancer vaccine biological immunotherapy 7 . Allergic known ingredient MV compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>mix vaccine , lung neoplasm , immunotherapy</keyword>
</DOC>